The Cannabis-Based Biotech Sector's Best Buyout Candidates
The cannabis industry is currently filled with thinly-traded public companies with shaky revenue projections and questionable cash flow, but it’s expected to grow over 400% over the next 7 years. Already, a handful of companies with growing patent portfolios are carving out large and profitable niches. Todd Hagopian, and Jason Spatafora, told us in July that some of these companies would be acquisition targets. Since then the market has proven them right as GW Pharma has emerged as a buyout candidate.
Todd started his Biotech fund at Marketocracy in March, 2011. His returns have averaged 28.12% since then, which compares nicely to the S&P 500’s 11.87% return over the same period. Over the last five and three year periods, he did better than the top U.S. Equity fund manager. Before taking anyone’s investment advice, you should always check out their track record. Here is Todd’s.
Ken Kam: It seems...
This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.
Follow us on Instagram
Connect with us on Linkedin